Back to results
US 8,287,865 B2Granted
Class I anti-CEA antibodies and uses thereof
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
Estimating the term…
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
A composition comprising a chimeric, humanized or human Class I anti-CEA antibody or antigen-binding fragment thereof, comprising the light chain variable region CDR (complementarity determining region) sequences SASSRVSYIH (SEQ ID NO:1);
A method of delivering a diagnostic and/or therapeutic agent, comprising administering to a subject a chimeric, humanized or human Class I anti-CEA antibody or fragment thereof, wherein the Class I anti-CEA antibody or fragment thereof comprises the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1);
A method of treating cancer, comprising administering to a subject a chimeric, humanized or human Class I anti-CEA antibody or fragment thereof, wherein the Class I anti-CEA antibody or fragment thereof comprises the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1);
Dependencies are inferred from the claim text.